Glycoconjugation processes and compositions
View Patent ↗The invention provides eTEC linked glycoconjugates comprising a saccharide covalently conjugated to a carrier protein through a (2-((2-oxoethyl)thio)ethyl)carbamate (eTEC) spacer, immunogenic compositions comprising such glycoconjugates, and methods for the preparation and use of such glycoconjugates and immunogenic compositions.
1. A method of making a glycoconjugate comprising a saccharide conjugated to a carrier protein through a (2-((2-oxoethyl)thio)ethyl)carbamate (eTEC) spacer, comprising the steps of:
a) reacting a saccharide with 1,1′-carbonyl-di-(1,2,4-triazole) (CDT) or 1,1′-carbonyldiimidazole (CDI), in an organic solvent to produce an activated saccharide;
b) reacting the activated saccharide with cystamine or cysteamine or a salt thereof, to produce a thiolated saccharide;
c) reacting the thiolated saccharide with a reducing agent to produce an activated thiolated saccharide comprising one or more free sulfhydryl residues;
d) reacting the activated thiolated saccharide with an activated carrier protein comprising one or more α-haloacetamide groups, to produce a thiolated saccharide-carrier protein conjugate; and
e) reacting the thiolated saccharide-carrier protein conjugate with (i) a first capping reagent capable of capping unconjugated α-haloacetamide groups of the activated carrier protein; and/or (ii) a second capping reagent capable of capping unconjugated free sulfhydryl residues;
whereby an eTEC linked glycoconjugate is produced.
2. The method of claim 1 , wherein the capping step e) comprises reacting the thiolated saccharide-carrier protein conjugate with (i) N-acetyl-L-cysteine as a first capping reagent, and/or (ii) iodoacetamide as a second capping reagent.
3. The method of claim 1 , further comprising a step of compounding the saccharide by reaction with triazole or imidazole to provide a compounded saccharide, wherein the compounded saccharide is shell frozen, lyophilized and reconstituted in an organic solvent prior to step a).
4. The method of claim 1 , further comprising purification of the thiolated polysaccharide produced in step c), wherein the purification step comprises diafiltration.
5. The method of claim 1 , wherein the method further comprises purification of the eTEC linked glycoconjugate by diafiltration.
6. The method of claim 1 , wherein the organic solvent in step a) is a polar aprotic solvent selected from the group consisting of dimethyl sulfoxide (DMSO), dimethylformamide (DMF), dimethylacetamide (DMA), N-methyl-2-pyrrolidone (NMP), acetonitrile, 1,3-Dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone (DMPU) and hexamethylphosphoramide (HMPA), or a mixture thereof.
7. The method of claim 1 , wherein the saccharide:carrier protein ratio (w/w) is between 0.2 and 4, or between 0.4 and 1.7.
8. The method of claim 1 , wherein the saccharide is a capsular polysaccharide derived from S. pneumonia and said capsular polysaccharide is selected from the group consisting of pneumococcal (Pn) serotype 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and 33F capsular polysaccharides.
9. The method of claim 1 , wherein the saccharide is a capsular polysaccharide derived from N. meningitidis.
10. The method of claim 1 , wherein the carrier protein is CRM 197 .
11. An immunogenic composition comprising the glycoconjugate of claim 1 and a pharmaceutically acceptable excipient, carrier or diluent.
12. A glycoconjugate comprising a bacterial capsular polysaccharide conjugated to a carrier protein through a (2-((2-oxoethyl)thio)ethyl)carbamate (eTEC) spacer, wherein the polysaccharide is covalently linked to the eTEC spacer through a carbamate linkage, and wherein the carrier protein is covalently linked to the eTEC spacer through an amide linkage, as shown by formula (I)
13. The glycoconjugate of claim 12 , wherein the capsular polysaccharide is selected from the group consisting of Pn-serotype 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and 33F capsular polysaccharides.
14. The glycoconjugate of claim 12 , wherein the capsular polysaccharide is derived from N. meningitidis.
15. The glycoconjugate of claim 12 , wherein the polysaccharide has a molecular weight of between 10 kDa and 2,000 kDa, or between 50 kDa and 2,000 kDa.
16. The glycoconjugate of claim 12 , wherein the polysaccharide has a degree of O-acetylation between 75-100%.
17. The glycoconjugate of claim 12 , wherein the carrier protein is CRM 197 .
18. The glycoconjugate of claim 17 , wherein the CRM 197 comprises 2 to 20, or 4 to 16, lysine residues covalently linked to the polysaccharide through an eTEC spacer.
19. The glycoconjugate of claim 12 , wherein the saccharide:carrier protein ratio (w/w) is between 0.2 and 4, or between 0.4 and 1.7.
20. An immunogenic composition comprising the glycoconjugate of claim 12 and a pharmaceutically acceptable excipient, carrier or diluent.
21. The immunogenic composition of claim 20 , further comprising an additional antigen.
22. The immunogenic composition of claim 21 , wherein the additional antigen comprises a glycoconjugate of a capsular polysaccharide selected from the group consisting of Pn-serotype 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and 33F capsular polysaccharides.
23. The immunogenic composition of claim 20 , further comprising an adjuvant.
24. The immunogenic composition of claim 23 , wherein the adjuvant is an aluminum-based adjuvant selected from the group consisting of aluminum phosphate, aluminum sulfate and aluminum hydroxide.